T cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities)


We are delighted that you have chosen to enhance your educational journey in immuno-safety science by enrolling in this module. The "T cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities)" lecture is one of a series of 18 lectures included in the Introduction to Immuno-Safety Science module and is led by  Dr. Courtni Newsome at Bristol Myers Squibb. Please review the learning objectives below for more information on what you will learn in this lecture. 
If you are new to HESI and would like to learn more about our organization, please take a moment to visit our website at https://hesiglobal.org

Target Audience

This course is intended for the science professional or graduate student looking to learn the fundamental science and key considerations that are examined in immune safety assessment. Advanced topics and courses that take a deeper dive into specific scientific areas will be offered and recommended for the more experienced scientist with a firm grasp of the information highlighted in the introduction module.

Learning Objectives

  • Basic T cell biology review
  • Broad categories of T cell therapies and in what therapeutics areas they're most commonly used
  • Types of toxicities with these therapies
  • Future directions of these therapies?
Course summary
Available credit: 
  • 1.00 Participation
Course opens: 
Course expires: 
Courtni Newsome, PhD
Bristol Myers Squibb

Available Credit

  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

This platform, Ethos CE, works with most modern web browsers (e.g., Chrome, Internet Explorer, MS Edge, Safari). Contact itc@hesiglobal.org if you are having any difficulties with this platform.